TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06909110: Viral Specific T-Lymphocytes to Treat Infection With Adenovirus, Cytomegalovirus or Epstein-Barr Virus in Patients With Compromised Immunity

Sponsor: Jessie L. Alexander · Phase: PHASE1/PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 25 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$645,150

Rescue Site Savings

+$439,875

Unlock Full NCT06909110 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06909110 Rescue Dossier →